Brainstorm Cell Therapeutics Inc. GHDN.F Stock
Brainstorm Cell Therapeutics Inc. Price Chart
Brainstorm Cell Therapeutics Inc. GHDN.F Financial and Trading Overview
| Brainstorm Cell Therapeutics Inc. stock price | 0.55 EUR |
| Previous Close | 2.48 EUR |
| Open | 2.48 EUR |
| Bid | 2.44 EUR x 0 |
| Ask | 2.52 EUR x 0 |
| Day's Range | 2.44 - 2.44 EUR |
| 52 Week Range | 1.25 - 4.45 EUR |
| Volume | 1K EUR |
| Avg. Volume | 63 EUR |
| Market Cap | 96.16M EUR |
| Beta (5Y Monthly) | -0.418309 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.37 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.5 EUR |
GHDN.F Valuation Measures
| Enterprise Value | 99.19M EUR |
| Trailing P/E | N/A |
| Forward P/E | -2.5957448 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.095 |
Trading Information
Brainstorm Cell Therapeutics Inc. Stock Price History
| Beta (5Y Monthly) | -0.418309 |
| 52-Week Change | -0.23% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.45 EUR |
| 52 Week Low | 1.25 EUR |
| 50-Day Moving Average | 2.54 EUR |
| 200-Day Moving Average | 2.42 EUR |
GHDN.F Share Statistics
| Avg. Volume (3 month) | 63 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 39.41M |
| Float | 32.73M |
| Short Ratio | N/A |
| % Held by Insiders | 24.00% |
| % Held by Institutions | 10.62% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -90.96% |
| Return on Equity (ttm) | -497.065% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -24220000 EUR |
| Net Income Avi to Common (ttm) | -23976000 EUR |
| Diluted EPS (ttm) | -0.6 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.23M EUR |
| Total Cash Per Share (mrq) | 0.06 EUR |
| Total Debt (mrq) | 3.68M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.281 |
| Book Value Per Share (mrq) | -0.126 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -19618000 EUR |
| Levered Free Cash Flow (ttm) | -10421250 EUR |
Profile of Brainstorm Cell Therapeutics Inc.
| Country | Germany |
| State | NY |
| City | New York |
| Address | 1325 Avenue of Americas |
| ZIP | 10019 |
| Phone | 201 488 0460 |
| Website | https://www.brainstorm-cell.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 41 |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Q&A For Brainstorm Cell Therapeutics Inc. Stock
What is a current GHDN.F stock price?
Brainstorm Cell Therapeutics Inc. GHDN.F stock price today per share is 0.55 EUR.
How to purchase Brainstorm Cell Therapeutics Inc. stock?
You can buy GHDN.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Brainstorm Cell Therapeutics Inc.?
The stock symbol or ticker of Brainstorm Cell Therapeutics Inc. is GHDN.F.
Which industry does the Brainstorm Cell Therapeutics Inc. company belong to?
The Brainstorm Cell Therapeutics Inc. industry is Biotechnology.
How many shares does Brainstorm Cell Therapeutics Inc. have in circulation?
The max supply of Brainstorm Cell Therapeutics Inc. shares is 68.34M.
What is Brainstorm Cell Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Brainstorm Cell Therapeutics Inc. PE Ratio is now.
What was Brainstorm Cell Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Brainstorm Cell Therapeutics Inc. EPS is -0.37 EUR over the trailing 12 months.
Which sector does the Brainstorm Cell Therapeutics Inc. company belong to?
The Brainstorm Cell Therapeutics Inc. sector is Healthcare.